Date prepared: July 22, 2023<\/p>\n\n\n\n
Abbreviated name of the issuer:<\/p>\n\n\n\n
CELON PHARMA S.A. <\/p>\n\n\n\n
Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022<\/p>\n\n\n\n
Legal basis<\/p>\n\n\n\n
Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodic information<\/p>\n\n\n\n
Content of the report:<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (\u201cCompany\u201d) informs that the Ordinary General Meeting (\u201cOGM\u201d) of the Company held on June 22, 2022 adopted a resolution on coverage of loss and payment of the dividend for the financial year 2022.<\/p>\n\n\n\n
The Ordinary General Meeting decided that:<\/p>\n\n\n\n
a) the Company’s net loss for the financial year starting on January 1, 2022 and ending on December 31, 2022 in the amount of PLN 39,277 thousand will be covered by the part of the Company\u2019s supplementary capital created from the share premium.<\/p>\n\n\n\n
b) the Company will pay out the dividend in the amount of PLN 0.09 (nine groszy) per one share, which amounts to a total of PLN 4,595,085.00, whereas the amount of the recommended dividend will be paid out from the part of the Company’s supplementary capital created from the profit generated in the previous years and complies with the requirements of Article 348 of the Commercial Companies Code.<\/p>\n\n\n\n
51,056,500 shares in the Company are covered by the dividend.<\/p>\n\n\n\n
June 30, 2023 was set as the dividend record date, and the dividend is to be paid out on July 6, 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"